**PRAMOD KUMAR MISTRY, MD, PhD**

**CURRENT POSITION**

Professor of Medicine,

Professor of Pediatrics,

Professor of Cellular & Molecular Physiology,

Director: Yale Gaucher Center for Lysosomal Diseases

Yale School of Medicine

Attending Physician,

Yale New Haven Hospital: Klatskin Liver Service and Liver Transplant Service.

Correspondence:

Department of Internal Medicine

(Digestive Diseases)

333 Cedar Street/LMP 1080

P.O. Box 208019

New Haven, CT 06520-8019

Campus & Fed-Ex Address:

One Gilbert Street, TAC Building, Room S227B

New Haven, CT 06519

Tel: 203 785 3412

Fax: 203 785 7273

Email: Pramod.mistry@yale.edu

**PERSONAL STATEMENT:**

I am Professor of Medicine (Digestive Diseases), Pediatrics and Cellular & Molecular Physiology, at Yale School of Medicine. I completed PhD/MB BS at University of London and concluded my initial training in Internal Medicine and Gastroenterology at London’s UCL/Royal Free Hospital School of Medicine and Addenbrooke’s Hospital, Cambridge. In 2001, I was recruited as Associate Professor of Medicine in the Section of Digestive Diseases at Yale School of Medicine. From the beginning, my career has been dedicated to clinical research, advocacy, and education in Gaucher disease. My research is focused on comprehensive delineation of Gaucher disease through phenotype annotation, genomic annotation, modifier gene discovery, biomarker discovery/validation and therapies. My lab developed the first authentic mouse model of Gaucher disease. The advances in understanding disease mechanisms in the Gaucher mouse model informed clinical research on biomarker validation, osteopenia, and therapy. I run a dedicated inherited metabolic liver disease clinic offering the entire range of therapies from small molecules, recombinant enzyme replacement, and liver transplant.

Families afflicted with rare inherited disease are severely underserved having limited access to knowledgeable expert physicians and therapies; it is not uncommon for patients to have prolonged diagnostic odysseys while they suffer from severe complications. For last 2 decades, my advocacy work in this area includes playing a key role in building national centers of excellence in Gaucher disease in UK and US as well as humanitarian treatment programs for children with Gaucher disease in Egypt, China and India. I am Chairman of the International Gaucher Disease Registry, the largest rare disease registry in the world. I am most proud of having trained large number of physicians throughout the world to become experts in this rare disease area to treat a highly underserved patient population.

For past 10 years, biomarker discovery and validation has been a major focus of our research efforts to improve care of patients affected with this complex disease. I was an invited speaker at FDA meeting convened by The Office of Translational Sciences on September 20, 2010 on biomarkers of Gaucher disease. I developed the theme for biomarker discovery based on FDA Critical Path Opportunities List to identify candidate biomarkers in our mouse models followed by functional studies and validation in patient populations. In 2010, we reported in the Proceedings of National Academy of Sci (USA) (Mistry PK, Liu J, Yang M, Nottoli T, et al,Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage. Proc Natl Acad Sci U S A. 2010;107(45): p. 19473-8. PMID: 20962279) wherein we described how glucosylsphingosine could be utilized as a biomarker. Indeed, as requested of each speaker at the meeting to present a final slide of ‘biomarker wish-list’ I included circulating levels of glucocosylsphingosine. In fact, this meeting set up the collaboration between Aerts and our labs that resulted in paper one year later reporting the properties of glucosylsphingosine to function as highly meaningful biomarker of Gaucher disease (Dekker N, …Mistry PK, Boot RG, Aerts JM., Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response. Blood. 2011; 118(16): p. e118-27. PMID: 21868580). Over the years, we have built a solid body of evidence in definitive papers linking glucosylsphingosine and new biomarkers to disease severity, response to therapy and various pathological aspects of Gaucher disease.

I was recently recognized by Expertscape World expert in Sphingolipidosis: <https://twitter.com/Daily_Experts/status/1142079734312050689> (accessed 6/20/19)

**EDUCATION**

08/1972 – 06/1975 B.Sc. (Hons) Queen Elizabeth College, University of London. Physiology/ Biochemistry

08/1975 – 10/1978 PhD, St Thomas’s Hospital School of Medicine, University of London

0/8/1978 – 06/1983 MB BS Royal Free UCL School of Medicine

1987 Member of Royal College of Physicians (by examination)

 – elected Fellow of the Royal College of Physicians 1999

2007 MA (*privatum)* Yale University

2015 M.D. University of the State of New York, MD conferral by the Boards of Regents

### **POST-DOCTORAL TRAINING**

08/1983 – 07/84 Internship: House Officer in Medicine Royal Free Hospital and

 House Officer in Surgery, Dewsbury General Hospital

08/1984 – 07/1986 Residency: Rotating Senior House Officer in Medicine (Nephrology, Cardiology,

 Infectious diseases and General Internal Medicine)

08/1986-12/1989 Chief Resident: Registrar in Hepatology, Gastroenterology, Oncology and Internal Medicine, Royal Free Hospital, London

01/1990-10/1994 Fellowship: Senior Registrar Internal Medicine, Metabolic Medicine and Hepatology, Addenbrooke’s Hospital, Cambridge

**ACADEMIC APPOINTMENTS**

 University of Cambridge Clinical School, Cambridge

1989-1994 Clinical Lecturer in Medicine

 Department of Medicine

 Royal Free UCL School of Medicine, London

1994 – 1998 Senior Lecturer (Hon Consultant) in Medicine

 Department of Medicine

 Mount Sinai School of Medicine

1998 - 2001 Associate Professor,

 Departments of Human Genetics and Medicine

 Yale University School of Medicine

2001 – 2005 Associate Professor of Medicine (Section of Digestive Diseases)

2005 – 2013 Professor of Pediatrics and Medicine, Chief, Section of Pediatric Gastroenterology and Hepatology

07/2013 – present Professor of Medicine (Digestive diseases) and Pediatrics (Gastroenterology) and Cellular & Molecular Physiology.

# HOSPITAL APPOINTMENTS

 Royal Free Hospital, London

01/1994-04/1998 Attending Physician, Department of Medicine

 Medical Co-Director, Liver Transplant Program

 Founding Director, NHS-funded Gaucher disease center

 Mount Sinai School of Medicine

05/1998 – 10/2001 Attending Physician

 Director, Comprehensive Gaucher Disease Treatment Center

 Yale New Haven Hospital

11/2001-10/2005 Attending Physician (Internal Medicine/GI)

 Medical Director of Liver Transplant Program

11/2005 – 06/2013 Yale New Haven Children’s Hospital

Attending Physician, Chief, Pediatric GI

 Medical Director of Pediatric Liver Transplant Program

 Director of Inherited Metabolic Liver disease clinic

07/2013 – present Yale New Haven Hospital

 Attending Physician/Transplant Hepatologist (Hepatology)

**HONORS AND AWARDS**

1980 Foulke's Foundation Fellowship

1995 Alan Gordon Memorial Award of the Gaucher Association (UK)

1997/8 Founding Director, National Center of Excellence for Gaucher Disease, Royal

 Free Hospital, London

1998 Elected Fellow of the Royal College of Physicians (London)

1999 Physician of the Year Award, Genetic Disease Foundation, New York

2006-08 Chairman of Medical Advisory Board, American Liver Foundation (Connecticut Chapter

2002 Max Millman Memorial Lecturer, Baystate Medical Center, Springfield, MA

2003 Visiting Professor, University of Manitoba Medical School, Winnipeg. Ca

2004 Visiting Professor, University of Connecticut GCRC

2005/2010 Nominated for Alice Bohmfalk Teaching Award, Yale University.

2005/2008 Award from National Gaucher Foundation for contributions to Gaucher disease

2007 MA (*privatim*) Yale University

2010 Fellow of the Royal Society of Medicine

2004 – Present Listed in The Best Doctors in America

2015-present Chairman of MAB of Project HOPE Gaucher Initiative for children in Egypt

2017 Elected Fellow of the American Association for Study of the Liver

2020 Nominated for Leonard Tow Humanism in Medicine Award

**BOARD CERTIFICATION**

1994 Certificate of Specialist Training in Gastroenterology, General Medical Council of UK (inactive)

1998 ECFMG

1999 American Board of Internal Medicine (active)

**LICENSURE**

Admitted to the General Medical Council of United Kingdom,

License # 2818678

State of New Jersey, License # 25MA07679000 (Inactive)

The University of the State of New York, Medical License # 214606

 DEA # BM 5991422 (Active)

State of Connecticut, License # 039656 (Active)

# EDITORIAL RESPONSIBILITIES

2010 – 2017 Editorial Board, Hepatology

2004 – Present Editorial Board, World Journal of Gastroenterology

2006 – Present Editorial Board, Expert Reviews in Gastroenterology and Hepatology

2017 - Co-chief Editor, Advances in Gaucher Disease

2018 - Editorial Board, Expert Reviews in Molecular Medicine

**NATIONAL AND INTERNATIONAL COMMITTEE ASSIGNMENTS**

1998-Present Elected to the Medical Advisory Board, National Gaucher Foundation, USA

1998-Present Elected to Medical Advisory Board, Gaucher Association, UK

1998-Present Regional coordinator, International Gaucher registry.

1999 Member of NIH site visit panel Cincinnati Children’s Hospital GCRC

2000 Referee for Welcome Trust, UK.

2000 Referee for Cochrane Cystic Fibrosis and genetic disorders group

2004 Medical Advisory Board, Children’s Fund for Glycogen Storage Disease type 1a.

2004 Medical advisory Board, WISDOM, Wilson Disease Association of India.

2004 Moderator for 2004 AASLD oral presentations: Metabolic and Inherited Disease

2007 Course director, AALSLD/NASPGHAN symposium ‘Fibrocystic diseases of the liver’

2007 Chairman, American Liver Foundation Medical Advisory Board, Connecticut Chapter

2001 - Present Gaucher Generation Program Review Committee

2008 Course Director NASPGHAN AASLD symposium ‘Advances in Inherited Cholestasis Syndromes’

2008 – 2015 Abstract Review Committee, Chair, DDW and AASLD

2009 Chairman of Project Hope Humanitarian Program for Gaucher disease (on medical advisory board since 2001 and Chairman since 2009)

2010 Member, DSMB, NIDDK Pediatric Acute Liver Failure Study Group (PALF)

2011/12/17 Member of Review Panel FDA Office of Orphan Drug Development

2012 External Reviewer for AXA Research Fund, Paris.

2012 External Reviewer for Medical Research Council (UK) RFA on Stratified Medicine

2014 Grant Reviewer, Telethon Foundation, Italy.

2017 Reviewer for Israel Science Foundation

2017 External Reviewer, Vici programme ZonMw, The Netherlands

NIH Study Section Member:

 2002 Ad Hoc Member ZDK1 GRB-C (J1)

 2005 ZDK1 GRB-8(M8)

 2005 Special Emphasis Panel ZDK1 GRB-4 M1

 2007 Special Emphasis Panel ZDK1 GRB-8 M3

 2009/2011 Special Emphasis Panel

 Chairman:

2014 NIDDK Special Emphasis Panel

Childhood Liver Disease Research Network ZDK1 GRB-7 M1 R

ZTR1 RD-8 01 1, Rare Disease Clinical Research

Date(s) of review: February 11, 2019 - February 22, 2019

2012 and 2017 FDA Grant Review Committee

2013 – current Review Committee Yale Clinical Scholars Program of Yale’s NIH Clinical Translational Research Award (CTSA)

2014 External Reviewer for Italian Telethon Research Foundation

2015 Chairman, R01 ancillary study section panel for the ChilDREN network

2014 - 2017 Member of American Liver Foundation Grants Committee

2016 – current Member of TAG (Therapeutic Advances in Genetic Diseases) study section

2017 – current External Scientific Consultant to NDDK for ChiLDReN

2017 Netherlands Organization for Scientific Research, NWO.

2017 – 2020 Member, Awards Committee of AALSD

2019 NIH NCAT Grant Review Panel, Washington DC. 02.20.2019

2020 Reviewer for The Wellcome Trust/ DBT India

2020 Reviewer for FWF Austrian Science Fund Erwin Schroedinger Programme

2021 Member of Parkinson disease genes Expert Curation panel

2021 Chairman, MAB, Internal Wilson Disease Registry

2021 Member of the Executive Committee of Yale Liver Center

**PROFESSIONAL SOCIETIES**

1992-Present Member, European Working Group on Gaucher Disease

1998-Present Member, American Association of Human Genetics

1998-Present Member, American Association of Study of the Liver

2006 Member, North American Society of Pediatric Gastroenterology, Hepatology and Nutrition.

2010 Member of Society for Study of Inborn Errors of Metabolism

# NATIONAL/INTERNATIONAL ORGANIZATIONS

American Society for the Study of the Liver, AASLD

North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN)

American Society of Human Genetics ASHG

Society of Inborn Errors of Metabolism SSIEM

Internal Liver Transplant Society ILTS.

**DEPARTMENTAL, UNIVERSITY and HOSPITAL SERVICE**

Yale Medical School

2006 - 2015 Medical School Selection Committee

2007 Search Committee for Chief of Solid Organ Transplantation

2011 Search committee for Chief of Pediatric Surgery

2011 Search committee for Medical Director of Pediatric Liver Transplant Program

2013 Search committee for Chief of Transplantation

2010 – Present Appointment & Promotions Committee (Term) of Yale School of Medicine

2006 - 2012 Appointment & Promotions Committee, Department of Pediatrics, YSM.

2013 – current Appointments & Promotions Committee, Department of Medicine

**EDUCATIONAL ACTIVITIES**

YSM Teaching Responsibilities

2001 – Present Clinical correlations (first year medical students) 2/8 sessions

2005 – Present Bench to Bedside seminars (first year medical students)

2001 – Present Digestive Disease Module (second year medical students)

2013 – Present First Year Physiology class

2001 - Present Didactic program teaching of adult and pediatric GI fellows

# MAJOR RESEARCH INTERESTS

# Clinical phenotyping and genomics of inherited metabolic liver diseases

# Gaucher disease: natural history, modifier genes, disease mechanisms and therapies

* Wilson disease: natural history, genetic heterogeneity and natural history
* Glycogen storage disease type 1a: determinants of hepatocellular adenocarcinoma
* Genetic syndromes leading to acute liver failure in children
* Genetic basis of biliary atresia

**ACTIVE GRANT AND CONTRACT SUPPORT**

|  |
| --- |
| **Active****ACTIVE**Genzyme-Sanofi Mistry (PI) 1/01/13 – 6/31/2022 $599,639 4.8 Calendar MonthsCenter of Excellence in Clinical Translational Research in Gaucher Disease Major aims are phenotype stratification, transcriptome analysis and hypothesis-driven research in International Gaucher Registry.Sanofi-Aventis Mistry (PI) 2/6/2015 – 2/5/2020 $65,217 .12 Calendar MonthsGaucher Generation Program Established Investigator Award: Studies to Delineate Specific Phenotypes of Gaucher disease and decipher respective biomarker signatures and genetic underpinningsNIH NINDSS. Chandra (PI)Role: Co-Investigator 2/1/19 – 11/30/2023 $40,000 0.6 Calendar MonthsRole of Glucosylsphingosine in Parkinson Disease and Dementia with Lewy Bodies: Goal of this study is to investigate role of acid ceramidase and GBA2 enzyme in glucosylsphingosine-mediated alpha synuclein aggregation using mouse models and patient-derived induced PSC cell linesGenzyme-SanofiMistry (PI) 2018-2021 0.6 Calendar MonthsMulticenter phase 2 clinical trial of glucosylceramide synthase for type 3 Gaucher disease |

**RECENT EXTRAMURAL LECTURES (SELECTED)**

* 4/26/21: International Gaucher Alliance: Managing bone complications of Gaucher disease
* 4/11/20: South Asia Lysosomal Disease Annual Conference: Covid19 and Gaucher disease
* Lysosomal disease WORLD conference 2021 Speaker and Chairman, Rare Disease Registries: Pioneering Real World Evidence’
* 10/24/20: Spanish Gaucher Association ‘Covid19 and Gaucher disease’
* 10/28/20: Virtual seminar for hematologists in Thailand. Malaysia and Singapore “Gaucher disease beyond splenomegaly and thrombocytopenia’
* 10/5/20: European Working Group on Gaucher Disease: EWGGD Outcomes after 4.5 years of eliglustat treatment in ENGAGE trial.
* June 15, 2020 International Cerdelga Advisory Board, Virtual Meeting, Chairman and speaker.
* May 23, 2020: Internal Gaucher Alliance, Virtual Meeting, Speaker: Clinical Trials in rare disease.
* February 5-6, WORLD Lysosomal Meeting, Orlando, Speaker, Moderator.
* December 6, 2019: Cedars Sinai Medical Center, Los Angeles: Annual Lysosomal Disease Conference key note speaker: Role of glucosylsphingosine in Gaucher disease.
* November 15-16: LATAM Gaucher bone disease conference: Scientific Committee Member, Moderator, speaker.
* July 12th, 2019: Jekei University School of Medicine, Tokyo. Fifth International Forum on Gaucher Disease. Clinical and Biochemical advances in Gaucher disease.
* Invited speaker, GD/ASMD Emerging Leaders Program, Tokyo. 5.18.2019. Current and new biomarkers.
* Invited speaker, WORLD Symposium Sphingolipids- opening a black box, Orlando, 2.06.2019 ‘Role of sphingolipids in Gaucher disease pathophysiology’
* Keynote speaker, Indian Society of Inborn Errors of Metabolism, ISIEM, Pune, India. 01.19.2019. Gaucher disease – a model for phenotypic diversity and therapeutics
* Grand Rounds speaker, Mayo Clinic Phoenix 12.13.2018 ‘Understanding the link between Gaucher disease and myeloma’
* Invited speaker at Amsterdam Future of Biomarkers in Gaucher disease 9.22.18 “ Glucosylsphingosine, a key biomarker of Gaucher disease.
* Presidential plenary speaker, SSIEM, Athens August 31, 2018 ‘Cancer risk in inborn errors of metabolism’
* Grand Rounds, Maimonides Hospital, June 8, 2018
* Invited speaker and co-organizer, FDA minisymposium ‘ Sphingolipids and cancer: Lessons from Gaucher disease’, April 23, 2018
* South Asia Lysosomal Disease Conference: Key note lecture. New Delhi. April 21m, 2018
* Grand Rounds, Beth Israel Deaconess Medical Center, Department of Hematology and Oncology. November 15, 2017
* Interurban Clinical Club, 216th Meeting. Yale School of Medicine. Rare Gaucher disease informing common diseases. November 3rd, 2017.
* London Health Science Center, Ontario. GCS inhibition as treatment of Gaucher disease. September 13, 2017
* BC Children’s Hospital, university of British Columbia, Vancouver. Advances in Treatment of Gaucher disease. September 12, 2017.
* Gaucher Leadership Academy (organizer, co-moderator with Professor Timothy Cox. Eliglustat: real world experience. Mainz. June 2nd and 3rd.
* July 5, 2017: Yale Partnership for global Health Program. Invited speaker: Clinical Translational Research in Gaucher disease, relevance to common diseases.
* April 7 and 8, 2017: ILTS Alex Mowat Symposium, London: Invited Lecture: Can the need for liver transplantation be eliminated in 25 years’ time – gene therapy and small molecules in the management of liver disease
* November 19, 2016: 4th Gaucher disease forum: Tokyo Special Lecture

“Past, Present and Future of Gaucher Disease management”

Chair: Director of Advanced Clinical Research Center, Institute of Neurological Diseases

Emeritus Professor, The Jikei University School of Medicine, Yoshikatsu Eto

Speaker: Yale University School of Medicine, Professor, Pramod K. Mistry, MD, PhD, FRCP,

* October 14-15: Second Middle East North Africa Rare Disease Summit, Dubai.

Meeting Chair and Speaker for following talks:

Therapeutic advances in Gaucher disease and novel oral SRT

Developing and implementing regional guidelines for diagnosis and treatment of Gaucher disease around the world.

* September 24-25, 2016: New Delhi.

2nd South Asia LSD Symposium, 2016 “25 years of treatment with Enzyme replacement therapy: Learnings and New frontiers”

Plenary lecture: Gaucher Disease: Recent advances in Gaucher Disease

Debate: BMT in Gaucher disease - against

* 3rd Latin American Gaucher disease Conference, Buenos Aires. Argentina.

August 4-6, 2016

Lectures:

The lysosome: New pathophysiological perspectives and roll of glucocerebrosidase. What have we learned from stem cell models?

Bone disease markers: biomarkers for chronic inflammation

The role of substrate reduction therapy on the treatment of Gaucher patients

* Invited speaker at Cambridge – Yale Transplant Course, Yale club, NYC: NKT cells in liver immunity, October 2, 2015.
* Invited speaker, Boston Children’s Hospital, Division of Genetics and Genomics. June 16, 2015. Neuronopathic Gaucher disease.
* Invited speaker DDW May 19, 2015, Washington DC. Exome Analysis in Diagnosis and Management of Pediatric Liver Failure in Translations Symposium: Challenges and Opportunities in Pediatric Liver Diseases
* Invited speaker, moderator: LATAM Gaucher Conference, Rio de Janeiro. May 7,8, 2015
* Invited speaker, Nordic Gaucher Association 20th Anniversary Symposium, Stockholm, March 17th, 2015.
* Invited speaker Gaucher Leadership Forum, Berlin March 27 and 28, 2015: Novel substrate reduction therapy for Gaucher disease.
* Invited speaker to Lysosomal Disease Network CME Program ‘Advancing the Management of Gaucher disease’ February 11, 2015, Orlando.
* Key note speaker at Joel Barlow High School 2014 Science Symposium: Advice for a Young Scientist
* Invited speaker: Italian Gaucher Association 10th Anniversary Keynote Address, Genoa, October 13, 2014: Pathophysiologic Basis of phenotypic diversity in Gaucher disease and modifier genes.
* Invited speaker, 2nd International Bone Disease Conference in Gaucher disease, Seoul, S Korea. Pathophysiologic basis of skeletal manifestations in Gaucher disease: insights from mouse models.
* Invited speaker at Armed Medical College, Pune, India on Golden Jubilee of AFMC Department of Pediatrics Symposium, September 31, 2014 ‘Advances in Gaucher disease’
* Invited speaker to AECM Liver Center Seminar Series May 7, 2014: Rare disease Research in Gaucher disease – Beyond Macrophage Lipidosis.
* Invited speaker 11th European Working Group on Gaucher disease, Haifa, Israel. Role of GBA2 in Gaucher disease
* Asian Society of Inherited Metabolic Disease and Japanese Society of Inherited Metabolic Diseases Joint Meeting, Chiba, Japan Invited speaker “Future treatment of Gaucher disease. November 2013

15th Asia LSD Symposium, Chiba, Japan. Gaucher disease: Translating clinical and basic research into improved outcomes. November 2013

* European Gaucher Leadership Forum, Madrid, Member of Scientific Advisory Board, Speaker and Moderator, November 2013
* 1st International Conference on Bone Involvement in Gaucher disease, Rio de Janeiro: Chair, Invited speaker and Moderator July 2013
* Catholic University of Chile, Clinical Hospital, Santiago. Grand Rounds: Inherited Metabolic Liver Diseases Presenting with Liver Failure. 7/2/13
* Clinica Las Condes, Santiago. Grand Rounds: Metabolic Liver Diseases. 7/1/13
* 14th North American Lysosomal Disease Registries Meeting: Towards value-based medicine in treatment of lysosomal diseases. Chair, Speaker and Moderator. June 2013
* UCLA Genetics Symposium: Invited speaker March 2013
* Department of Molecular & Cellular Physiology, Yale School of Medicine: Invited research lecture 2012
* Gaucher Leadership Forum: Chair of Scientific Advisory Board, Speaker and Moderator, Munich, Germany, 2012
* International Symposium on Lysosomal Storage Diseases, London, Moderator, Speaker; Immunogenicity in Lysosomal Diseases, 2012
* Indian Association for the Study of the Liver, Mumbai. Invited lectures: Hemochromatosis; Fatty liver disease in children, 2012
* Royal Free UCL School of Medicine; Invited Research Talk: New Developments in Gaucher disease 2010
* Department of Medicine, Yale School of Medicine, Grand Rounds, 2010
* Primary Sclerosing Cholangitis Seeking a Cure Annual Meeting: Organizer and Speaker: Natural Course of PSC, Hartford, 2010
* **FDA Biomarker Qualification Workshop, Invited Speaker, 2010**
* Brigham and Women Hospital, Boston: Invited Research Talk: Syndromes due to GBA1 mutations, 2010
* Dean’s Workshop, Yale School of Medicine. Construction and characterization of genetically engineered mice. Invited Talk. 2010
* National Institutes of Health, Speaker, Parkinson disease in Gaucher disease, 2010
* National Gaucher Foundation Meeting, Invited speaker, 2010
* Value Based Medicine in Hepatology, University of Milano-Bicocca. Invited Talk on Value Based Medicine for inherited metabolic liver diseases, Milan. 2009
* Max Millman Symposium Speaker, Baystate Hospital, Springfiled, MA, 2009
* Latin American Symposium on Lysosomal Storage Diseases, Invited Research Talk, Cancum, Mexico. 2009
* European Society of Pediatric Gastroenterology and Hepatology Translational Medicine Symposium, London. Invited Speaker: How to create a KO mouse model; Small molecule and enzyme therapies.
* Invited speaker 1st and 2nd Gaucher Leadership Forum, Budapest and Milan. 2009 and 2010
* Rhode Island Hospital: Grand Round 2008
* Lysosomal Storage Diseases Club of Canada, Invited Research Talk, Vancouver, 2011
* Cleveland Clinic Grand Rounds, 2008
* CME University of Puerto Rico (with YSM), San Juan. Liver Transplantation for inherited Metabolic Liver Diseases, 2008
* Nordic Gaucher Association, Invited Talk. Norway. 2008
* NYU Medical Center, Grand Round. 2010

# STUDENTS, RESIDENTS, FELLOWS MENTORED (AT YALE)

|  | Training Period  | Title of Research Project | Current Position of Past Trainees /Source of Support of Current Trainees |
| --- | --- | --- | --- |
| Mohsen Basiri | 2021 -2022 | Biomarkers and modifier genes in Gaucher disease | Lysosomal Disease Fellowship Training Award. |
| Praveena Narayanan | 2020 - 2023 | Immune response to lysolipids in liver disease | Fellow in Investigative Hepatology T32 program |
| Nathaniel Kleytman | 2020 - 2021 | Biomarker response to eliglustat | Medical student |
| Yuliya Afinogenova | 2016 - current | Biomarker validation in Gaucher disease | Fellow in Rheumatology, YSM, YNHH |
| Yumiko Taguchi | 2014-current | Mechanisms underlying GBA mutation associated Parkinson disease | PhD student, Department of Cell Biology, Yale University. Co-mentor |
| Silvia Vilarinho | 01/14 – present(Primary Mentor K08;Primary Mentor Doris Duke CSD Award) | Genomic analysis of biliary atresia and other childhood liver diseases | Yale Physician-Scientist Postdoctoral Program: FellowAssistant Professor |
| Vagishwari Murugeshan | 20117-2018 | Biomarker validation in Gaucher disease | Fellow, Rheumatology, Boston University Hospital |
| Sarah Lo(YSM, Dept of Pediatrics) | 7/09-6/11 | Discovery of genetic modifiers of Gaucher disease/cancer phenotype | Assistant Professor of Pediatrics, Cornell Weil Medical College, NYC. Investigative Hematology T32 Yale School of Medicine and Lysosomal Disease Network NIH Fellowship |
| Philip Stein(YSM, Dept of Pediatrics) | 7/09-6/11 | Biomarker discovery and validation in Gaucher disease | Assistant Professor of Pediatrics, Director of Inflammatory Bowel Disease Program, St Christopher’s Hospital for Children.Lysosomal disease Training Fellowship, Genzyme Corporation |
| Sarah Wardman(YSM, Dept of Pediatrics) | 7/11-11/11 | Genetic basis of cancer in inborn errors of metabolism using whole exome sequencing | Visiting Scholar, King’s College Hospital, National Health Service, UK |
| Daniel Pearson(YSM, Dept of Pediatrics) | 6/07-9/07 and 6/08-9/08 | Risk of Parkinson’s disease in Gaucher disease | MD/PhD program Harvard Medical SchoolResident MGH |
| Gilberto Bultron(YSM, Dept of Pediatrics) | 7/05-6/08 | Risk of Parkinson’s disease in Gaucher disease | Assistant Professor of Pediatrics, Loma Linda University School of Medicine |
| Sam ChengYSM, Pediatric GI Fellow | 7/09-6/12 | Role of calcium sensing receptor in inflammatory bowel disease | Assistant Professor, University of Florida, Department of Pediatric GI |
| Mohini PatelYSM, pediatric GI Fellow | 7/11- 2013 | Biomarkers of IBD and exome capture sequencing in IBD/primary sclerosing cholangitis | Pediatric Gastroenterology, Morristown, NJ |
| Anthony Porto | 5/10- 2012 | Molecular genetic studies and enzyme therapy for lysosomal lipase deficiency | Associate Professor of Pediatrics (GI) and Vice chair. |
| Aileen Raizner (YSM, Dept of Pediatrics) | July 2010 - current | Annotating phenotypes in inborn errors of metabolism | Post-doctoral GI Trainee/T32 Investigative Hepatology Training Program, YSMAssistant Professor, Children’s Hospital of Montefiore. |
| Tamar Taddei | July 2003- June 2006 | Natural history of N370S Gaucher disease | Associate Professor of Internal Medicine and Director of Liver Cancer Program, VA, West Haven,  |
| Sohail Husain | 2004-2011 | Mechanisms of acute pancreatitis | Section Chief, Stanford Pediatric GI Section |
| Francis Chan | July 2005-July 2009 | Clinical spectrum of pulmonary vascular disease in Gaucher disease | Gastroenterologist, Connecticut Gastroenterology PC, New Haven |
| Uma Phatak | July 2007-June 2010 | Clinical and genetic spectrum of Wilson disease | Associate Professor of Pediatrics (GI), YSM |

PEER-REVIEWED PUBLICATIONS

1. Turner P, Miller N, Chrystie I, Coltart J, **Mistry P**, Nicoll A, Lewis B. Splanchnic production of discoidal plasma high-density lipoprotein in man. *Lancet*. 1979;1(8117):645-6. PMID: 85875
2. **Mistry P**, Miller NE, Laker M, Hazzard WR, Lewis B. Individual variation in the effects of dietary cholesterol on plasma lipoproteins and cellular cholesterol homeostasis in man. Studies of low density lipoprotein receptor activity and 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in blood mononuclear cells. *J Clin Invest*. 1981;67(2):493-502. PMID: 6257763
3. Owen JS, Goodall H, **Mistry P**, Harry DS, Day RC, McIntyre N. Abnormal high-density lipoproteins from patients with liver disease regulate cholesterol metabolism in cultured human skin fibroblasts. *J Lipid Res*. 1984;25(9):919-31. PMID: 6491539
4. Desai K, **Mistry P**, Bagget C, Burroughs AK, Bellamy MF, Owen JS. Inhibition of platelet aggregation by abnormal high-density lipoprotein particles in plasma from patients with hepatic cirrhosis. *Lancet*. 1989 Apr 1;1(8640):693-5. PMID: 2564508
5. Mistry PK, Smith SJ, Ali M, Hatton CS, McIntyre N, Cox TM., Genetic diagnosis of Gaucher's disease. *Lancet*. 1992; 339(8798): p. 889-92. PMID: 1348297
6. **Mistry PK**, Davies S, Corfield A, Dixon AK, Cox TM., Successful treatment of bone marrow failure in Gaucher's disease with low-dose modified glucocerebrosidase. *Q J Med*, 1992. 83(303): p. 541-6. PMID: 1484931
7. Newman CM, Bruun BC, **Mistry PK**, Weissberg PL, Shanahan CM. High expression of osteopontin mRNA in human macrophages but not human vascular smooth muscle cells in culture. *Ann N Y Acad Sci*. 1995; 760:381-2. PMID: 7785923
8. Newman CM, Bruun BC, Porter KE, **Mistry PK**, Shanahan CM, Weissberg PL Osteopontin is not a marker for proliferating human vascular smooth muscle cells. *Arterioscler Thromb Vasc Biol*. 1995;15(11):2010-8. PMID: 7583583
9. Byrne CD, Wareham NJ, **Mistry PK**, Phillips DI, Martensz ND, Halsall D, Talmud PJ, Humphries SE, Hales CN. The association between free fatty acid concentrations and triglyceride-rich lipoproteins in the post-prandial state is altered by a common deletion polymorphism of the apo B signal peptide. *Atherosclerosis*. 1996;127(1):35-42. PMID: 9006802
10. **Mistry PK**, Wraight EP, Cox TM., Therapeutic delivery of proteins to macrophages: implications for treatment of Gaucher's disease. *Lancet*. 1996; 348(9041): p. 1555-9. PMID: 8950883
11. Gordon FH, **Mistry PK**, Sabin CA, Lee CA Outcome of orthotopic liver transplantation in patients with haemophilia. .*Gut*. 1998 May;42(5):744-9. PMID: 9659174; PMC1727096
12. Papatheodoridis GV, Hamilton M, **Mistry PK,** Davidson B, Rolles K, Burroughs AK. Ulcerative colitis has an aggressive course after orthotopic liver transplantation for primary sclerosing cholangitis. *Gut*. 1998;43(5):639-44. PMID: 9824344
13. Nitu IC, Lee CA, Dhillon AP, **Mistry PK**. Management of liver failure in a haemophilic patient co-infected with human immunodeficiency and hepatitis C viruses. *Clin Lab Haematol*. 1999; 21(2):139-41. PMID: 10342075
14. Diaz GA, Gelb BD, Risch N, Nygaard TG, Frisch A, Cohen IJ, Miranda CS, Amaral O, Maire I, Poenaru L, Caillaud C, Weizberg M, **Mistry P**, Desnick RJ., Gaucher disease: the origins of the Ashkenazi Jewish N370S and 84GG acid beta-glucosidase mutations. *Am J Hum Genet*. 2000; 66(6): p. 1821-32. PMID: 10777718
15. Charrow J, Andersson HC, Kaplan P, Kolodny EH, **Mistry P**, Pastores G, Rosenbloom BE, Scott CR, Wappner RS, Weinreb NJ, Zimran A., The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. *Arch Intern Med*. 2000; 160(18): p. 2835-43. PMID: 11025794
16. Gu M, Cooper JM, Butler P, Walker AP, **Mistry PK**, Dooley JS, Schapira AH Oxidative-phosphorylation defects in liver of patients with Wilson's disease. *Lancet*. 2000;356(9228):469-74. PMID: 10981891
17. Butler P, McIntyre N, **Mistry PK**. Molecular diagnosis of Wilson disease. *Mol Genet Metab*. 2001;72(3):223-30. PMID: 11243728
18. Nagral A, Quaglia A, Sabin CA, Dhillon AP, Bearcroft CP, Millar A, Davies SE, **Mistry PK**, Davidson BR, Rolles K, Burroughs AK. Blood and graft eosinophils in acute cellular rejection of liver allografts. *Transplant Proc*. 2001; Jun;33(4):2588-93. PMID: 11406255
19. Weinreb NJ, Charrow J, Andersson HC, Kaplan P, Kolodny EH, **Mistry P**, Pastores G, Rosenbloom BE, Scott CR, Wappner RS, Zimran A., Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. *Am J Med*. 2002; 113(2): p. 112-9. PMID: 12133749
20. Sirrs S, Irving J, McCauley G, Gin K, Munt B, Pastores G, **Mistry P**., Failure of resting echocardiography and cardiac catheterization to identify pulmonary hypertension in two patients with type I Gaucher disease. *J Inherit Metab Dis*. 2002; 25(2): p. 131-2. PMID: 12118528
21. **Mistry PK**, Sirrs S, Chan A, Pritzker MR, Duffy TP, Grace ME, Meeker DP, Goldman ME., Pulmonary hypertension in type 1 Gaucher's disease: genetic and epigenetic determinants of phenotype and response to therapy. *Mol Genet Metab*. 2002; 77(1-2): p. 91-8. PMID: 12359135
22. Xu R, **Mistry P**, McKenna G, Emre S, Schiano T, Bu-Ghanim M, Levi G, Fiel MI., Hepatocellular carcinoma in type 1 Gaucher disease: a case report with review of the literature. *Semin Liver Dis*. 2005; 25(2): p. 226-9. PMID: 15918150
23. Andersson HC, Charrow J, Kaplan P, **Mistry P**, Pastores GM, Prakash-Cheng A, Rosenbloom BE, Scott CR, Wappner RS, Weinreb NJ; International Collaborative Gaucher Group U.S. Regional Coordinators., Individualization of long-term enzyme replacement therapy for Gaucher disease. *Genet Med*. 2005; 7(2): p. 105-10. PMID: 15714077
24. El-Beshlawy A, Ragab L, Youssry I, Yakout K, El-Kiki H, Eid K, Mansour IM, Abd El-Hamid S, Yang M, **Mistry PK**., Enzyme replacement therapy and bony changes in Egyptian paediatric Gaucher disease patients. *J Inherit Metab Dis*. 2006; 29(1): p. 92-8. PMID: 16601874
25. **Mistry PK**, Sadan S, Yang R, Yee J, Yang M., Consequences of diagnostic delays in type 1 Gaucher disease: the need for greater awareness among hematologists-oncologists and an opportunity for early diagnosis and intervention. *Am J Hematol*. 2007; 82(8): p. 697-701. PMID: 17492645
26. Weinreb NJ, Deegan P, Kacena KA, **Mistry P**, Pastores GM, Velentgas P, vom Dahl S., Life expectancy in Gaucher disease type 1. *Am J Hematol*. 2008; 83(12): p. 896-900. PMID: 18980271
27. Gathungu GN, Pashankar DS, Sarita-Reyes CD, Zambrano E, Reyes-Mugica M, Brueckner M, **Mistry PK**, Husain SZ. Microvillus inclusion disease associated with coarctation of the aorta and bicuspid aortic valve. *J Clin Gastroenterol*. 2008; Apr;42(4):400-3. PMID: 18277898
28. DeMayo RF, Haims AH, McRae MC, Yang R, **Mistry PK**., Correlation of MRI-Based bone marrow burden score with genotype and spleen status in Gaucher's disease. *AJR Am J Roentgenol*. 2008; 191(1): p. 115-23. PMID: 18562733
29. Taddei TH, Kacena KA, Yang M, Yang R, Malhotra A, Boxer M, Aleck KA, Rennert G, Pastores GM, **Mistry PK**., The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patients. *Am J Hematol*. 2009; 84(4): p. 208-14. PMID: 19260119
30. Shah AU, Sarwar A, Orabi AI, Gautam S, Grant WM, Park AJ, Shah AU, Liu J, **Mistry PK**, Jain D, Husain SZ. Protease activation during in vivo pancreatitis is dependent on calcineurin activation. *Am J Physiol Gastrointest Liver Physiol*. 2009; Nov;297(5): G967-73. PMID: 20501444
31. **Mistry PK**, Deegan P, Vellodi A, Cole JA, Yeh M, Weinreb NJ., Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis. *Br J Haematol*. 2009; 147(4): p. 561-70. PMID: 19732054
32. Grabowski GA, Kacena K, Cole JA, Hollak CE, Zhang L, Yee J, **Mistry PK**, Zimran A, Charrow J, vom Dahl S., Dose-response relationships for enzyme replacement therapy with imiglucerase/alglucerase in patients with Gaucher disease type 1. *Genet Med*. 2009; 11(2): p. 92-100. PMID: 19265748
33. Taddei TH, Dziura J, Chen S, Yang R, Hyogo H, Sullards C, Cohen DE, Pastores G, **Mistry PK**., High incidence of cholesterol gallstone disease in type 1 Gaucher disease: characterizing the biliary phenotype of type 1 Gaucher disease. *J Inherit Metab Dis*. 2010; 33(3): p. 291-300. PMID: 20354791
34. Stein P, Yu H, Jain D, **Mistry PK**., Hyperferritinemia and iron overload in type 1 Gaucher disease. *Am J Hematol*. 2010; 85(7): p. 472-6. PMID: 20575041
35. Stein P, Malhotra A, Haims A, Pastores GM, **Mistry PK**., Focal splenic lesions in type I Gaucher disease are associated with poor platelet and splenic response to macrophage-targeted enzyme replacement therapy. *J Inherit Metab Dis*. 2010; 33(6): p. 769-74. PMID: 20683668
36. **Mistry PK**, Liu J, Yang M, Nottoli T, McGrath J, Jain D, Zhang K, Keutzer J, Chuang WL, Mehal WZ, Zhao H, Lin A, Mane S, Liu X, Peng YZ, Li JH, Agrawal M, Zhu LL, Blair HC, Robinson LJ, Iqbal J, Sun L, Zaidi M., Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage. *Proc Natl Acad Sci U S A*. 2010;107(45): p. 19473-8. PMID: 20962279
37. Lo SM, Stein P, Mullaly S, Bar M, Jain D, Pastores GM, **Mistry PK**., Expanding spectrum of the association between Type 1 Gaucher disease and cancers: a series of patients with up to 3 sequential cancers of multiple types--correlation with genotype and phenotype. *Am J Hematol*. 2010; 85(5): p. 340-5. PMID: 20425796
38. Lo SM, McNamara J, Seashore MR, **Mistry PK**., Misdiagnosis of Niemann-Pick disease type C as Gaucher disease. *J Inherit Metab Dis*. 2010;33 Supl.:S429-33. PMID: 20882348
39. Hůlková H, Poupetová H, Harzer K, **Mistry P**, Aerts JM, Elleder M., Abnormal nonstoring capillary endothelium: a novel feature of Gaucher disease. Ultrastructural study of dermal capillaries. *J Inherit Metab Dis*. 2010; 33(1): p. 69-78. PMID: 20049530
40. Bultron G, Kacena K, Pearson D, Boxer M, Yang R, Sathe S, Pastores G, **Mistry PK**., The risk of Parkinson's disease in type 1 Gaucher disease. *J Inherit Metab Dis*. 2010; 33(2): p. 167-73. PMID: 20177787
41. Ayto RM, Hughes DA, Jeevaratnam P, Rolles K, Burroughs AK, **Mistry PK**, Mehta AB, Pastores GM., Long-term outcomes of liver transplantation in type 1 Gaucher disease. *Am J Transplant*. 2010; 10(8): p. 1934-9. PMID: 20659098
42. Ma MH, Bai HX, Park AJ, Latif SU, **Mistry PK**, Pashankar D, Northrup VS, Bhandari V, Husain SZ. Risk Factors Associated with Biliary Pancreatitis in Children. *J Pediatr Gastroenterol Nutr*. 2012; 54(5): 651-6 PMID: 22002481
43. Stein P, Yang R, Liu J, Pastores GM, **Mistry PK**., Evaluation of high density lipoprotein as a circulating biomarker of Gaucher disease activity. *J Inherit Metab Dis.* 2011; 34(2): p. 429-37. PMID: 21290183
44. Nagral A, Mewawalla P, Jagadeesh S, Kabra M, Phadke SR, Verma IC, Puri RD, Gupta N, Kishnani PS, **Mistry PK**., Recombinant macrophage targeted enzyme replacement therapy for Gaucher disease in India. *Indian Pediatr*. 2011; 48(10): p. 779-84. PMID: 22080680
45. **Mistry PK**, Weinreb NJ, Kaplan P, Cole JA, Gwosdow AR, Hangartner T., Osteopenia in Gaucher disease develops early in life: response to imiglucerase enzyme therapy in children, adolescents and adults. *Blood Cells Mol Dis.* 2011; 46(1): p. 66-72. PMID: 21112800
46. Lo SM, Liu J, Chen F, Pastores GM, Knowles J, Boxer M, Aleck K, **Mistry PK**., Pulmonary vascular disease in Gaucher disease: clinical spectrum, determinants of phenotype and long-term outcomes of therapy. *J Inherit Metab Dis*. 2011; 34(3): p. 643-50. PMID: 21445609
47. Dekker N, van Dussen L, Hollak CE, Overkleeft H, Scheij S, Ghauharali K, van Breemen MJ, Ferraz MJ, Groener JE, Maas M, Wijburg FA, Speijer D, Tylki-Szymanska A, **Mistry PK**, Boot RG, Aerts JM., Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response. *Blood*. 2011; 118(16): p. e118-27. PMID: 21868580
48. Cole JA, Taylor JS, Hangartner TN, Weinreb NJ, **Mistry PK**, Khan A., Reducing selection bias in case-control studies from rare disease registries. *Orphanet J Rare Dis*, 2011; 42(2): 424-35. PMID: 21910867
49. Hammer MB, Eleuch-Fayache G, Schottlaender LV, Nehdi H, Gibbs JR, Arepalli SK, Chong SB, Hernandez DG, Sailer A, Liu G, **Mistry PK**, Cai H, Shrader G, Sassi C, Bouhlal Y, Houlden H, Hentati F, Amouri R, Singleton AB. Mutations in GBA2 cause autosomal-recessive cerebellar ataxia with spasticity. *Am J Hum Genet*. 2013;92(2):245-51. PMID: 23332917
50. Cheng SX, Bai HX, Gonzalez-Peralta R, **Mistry PK**, Gorelick FS. Calcium ameliorates diarrhea in immunocompromised children. *J Pediatr Gastroenterol Nutr*. 2013;56(6):641-4. PMID: 23343935
51. Lo SM, Choi M , Liu J, Jain D, Boot RG, Kallemeijn WW, Aerts JM, Pashankar F, Kupfer G, Mane S, Lifton RP, **Mistry PK**. Phenotypic diversity in type 1 Gaucher disease: Discovering the Genetic Basis of Gaucher disease/hematological malignancy phenotype by whole exome capture and massively parallel sequencing. *Blood*.2012; 119(20):4731-40. PMID: 22493294
52. Stein P, Zhang C, Liu J, Pastores GM, Wang Z, Yang R, Cho J , Gregersen P, Zhao H, **Mistry PK**. Genome-wide Association Study of N370S Homozygous Gaucher Disease Reveals the Candidacy of CLN8 gene as a Genetic Modifier Contributing to Extreme Phenotypic Variation in Gaucher Disease. *Amer J Hematol*. 2012;87(4):377-83. doi: 10.1002/ajh.23118. PMID: 22388998
53. Khan A, Cole JA, Taylor JS, Hangartner TN, Weinreb NJ, **Mistry PK**. Risk factors for fractures and avascular osteonecrosis in Type 1 Gaucher disease – a study from the International Gaucher Registry. *J of Bone and Mineral Research*. 2012; 27(8):1839-48 PMID: 22692814
54. Yuen T, Iqbal J, Zhu LL, Sun L, Lin A, Zhao H, Liu J, **Mistry PK**, Zaidi M. Disease-drug pairs revealed by computational genomic connectivity mapping on GBA1 deficient, Gaucher disease mice. *Biochem Biophys Res Commun*. 2012. 422(4):573-7. PMID: 22588172
55. Liu J, Halene S, Yang M, Iqbal J, Yang R, Mehal WZ, Chuang WL, Jain D, Yuen T, Sun L, Zaidi M, **Mistry PK**. Gaucher disease gene GBA functions in immune regulation. *Proc Natl Acad Sci U S A*. 2012; 109(25): 10018-23. PMID: 226657632
56. **Mistry PK**, Liu J, Sun L, Chuang WL, Yuen T, Yang R, Lu P, Zhang K, Li J, Keutzer J, Stachnik A, Mennone A, Boyer JL, Jain D, Brady RO, New MI, Zaidi M. Glucocerebrosidase 2 gene deletion rescues type 1 Gaucher disease. *Proc Natl Acad Sci U S A*. 2014; 111(13):4934-9. PMID: 24639522
57. Nair S, Boddupalli CS, Verma R, Liu J, Yang R, Pastores GM, **Mistry PK**, Dhodapkar MV. Type II NKT-TFH cells against Gaucher lipids regulate B cell immunity and inflammation. *Blood*. 2014; 125(8): 1256-7PMID: 25499455
58. Vilarinho S, Choi M, Jain D, Malhotra A, Kulkarni S, Pashankar D, Phatak U, Patel M, Bale A, Mane S, Lifton RP, **Mistry PK**. Individual exome analysis in diagnosis and management of paediatric liver failure of indeterminate aetiology. *J Hepatol*. 2014 Nov;61(5):1056-63. PMID: 25016221
59. **Mistry PK**, E Lukina , H Ben Turkia, D Amato, H Baris, M Dasouki , M Ghosn, A. Mehta, S Packman, G Pastores, M Petakov, S Assouline, M Balwani, S Danda, E Hadjiev, A Ortega, S Shankar, MH Solano, L Ross, S Marulkar, MJ Peterschmitt (2015) A Novel Substrate Reduction Therapy for Gaucher Disease Type 1: Efficacy and Safety of Eliglustat in the Randomized, Double-Blind, Placebo-Controlled ENGAGE Trial. *JAMA*. 2015;313(7):695-706. doi: 10.1001/jama.2015.459. PMID: 25688781
60. Ningappa M, So J, Glessner J, Ashokkumar C, Ranganathan S, Min J, Higgs BW, Sun Q, Haberman K, Schmitt L, Vilarinho S, **Mistry PK**, Vockley G, Dhawan A, Gittes GK, Hakonarson H, Jaffe R, Subramaniam S, Shin D, Sindhi R. The Role of ARF6 in Biliary Atresia. *PLoS One*. 2015;10(9); PMID: 26379158
61. Balwani M, Burrow TA, Charrow J, Goker-Alpan O, Kaplan P, Kishnani PS, **Mistry P**, Ruskin J, Weinreb N. Recommendations for the use of eliglustat in the treatment of adults with Gaucher disease type 1 in the United States. *Mol Genet Metab*. 2016;117(2): 95-103. PMID: 26387627.
62. Nair S., Branagan A., Liu J., Boddupalli CS., **Mistry PK**., Dhodapkar MV., (equal contribution) Clonal Immunoglobulin against Lysolipids in the Origin of Myeloma. *N Engl J Med*. 2016; 374 (6): 555. PMID: 26863356.
63. Verma J, Thomas DC, Kasper DC, Sharma S, Puri RD, Bijarnia-Mahay S, **Mistry PK**, Verma IC. Inherited Metabolic Disorders: Efficacy of Enzyme Assays on Dried Blood Spots for the Diagnosis of Lysosomal Storage Disorders. *JIMD Rep*. 2016. PMID: 27008195.
64. Murugesan V, Lischuk A, Haims A, Lackman R, Brooks JS, Mankin H, **Mistry PK**. Case series and literature review of skeletal tumors and their incidence in the Gaucher disease population. *Am J Hematol*. 2016;91(7):736-41. doi: 10.1002/ajh.24398. No abstract available. PMID: 27102845
65. Lopez G, Kim J, Wiggs E, Cintron D, Groden C, Tayebi N, **Mistry PK**, Pastores GM, Zimran A, Goker-Alpan O, Sidransky E. Clinical course and prognosis in patients with Gaucher disease and parkinsonism. *Neurol Genet*. 2016; 2(2):e57. doi: 10.1212/NXG.0000000000000057. PMID: 27123476
66. Cohen IJ, Baris H, **Mistry PK**, Sands MS. Overcoming the Next Barriers to Successful Therapy. *Pediatr Endocrinol Rev*. 2016;13 Suppl 1:629. No abstract available. PMID: 27491209
67. Murugesan V, Chuang WL, Liu J, Lischuk A, Kacena K, Lin H, Pastores GM, Yang R, Keutzer J, Zhang K, **Mistry PK**. Glucosylsphingosine is a key biomarker of Gaucher disease. *Am J Hematol*. 2016;91(11):1082-1089. doi: 10.1002/ajh.24491. PMID: 27441734
68. Sack J, Peaper DR, **Mistry P**, Malinis M. Clinical implications of Paracoccus yeeii bacteremia in a patient with decompensated cirrhosis. *IDCases*. 2017; 7:9-10. PMID: 27920982
69. Murugesan V, Liu J, Yang R, Lin H, Lischuk A, Pastores G, Zhang X, Chuang WL, **Mistry PK**. Validating glycoprotein non-metastatic melanoma B (gpNMB, osteoactivin), a new biomarker of Gaucher disease. *Blood Cells Mol Dis*. 2016. 68:47-53 pii: S1079-9796(16)30239-X. doi: 10.1016/j.bcmd.2016.12.002. PMID: 28003098
70. El-Beshlawy A, Tylki-Szymanska A, Vellodi A, Belmatoug N, Grabowski GA, Kolodny EH, Batista JL, Cox GF, **Mistry PK**. Long-term hematological, visceral, and growth outcomes in children with Gaucher disease type 3 treated with imiglucerase in the International Collaborative Gaucher Group Gaucher Registry. *Mol Genet Metab*. 2017;120(1-2):47-56. doi: 10.1016/j.ymgme.2016.12.001. PMID: 28040394
71. Raskovalova T, Deegan PB, Yang R, Pavlova E, Stirnemann J, Labarère J, Zimran A, **Mistry PK**, Berger M. Plasma chitotriosidase activity versus CCL18 level for assessing type I Gaucher disease severity: protocol for a systematic review with meta-analysis of individual participant data. *Syst Rev*. 2017;6(1):87. doi: 10.1186/s13643-017-0483-x. PMID: 28427477
72. **Mistry PK**, Batista JL, Andersson HC, Balwani M, Burrow TA, Charrow J, Kaplan P, Khan A, Kishnani PS, Kolodny EH, Rosenbloom B, Scott CR, Weinreb N. Transformation in Pre-treatment Manifestations of Gaucher Disease Type 1 during Two Decades of Alglucerase/Imiglucerase Enzyme Replacement Therapy in the International Collaborative Gaucher Group (ICGG) Registry. *Amer J Hematol*, 2017;92(9); 929-939 doi: 10.1002/ajh.24801. PMID: 28569047
73. **Mistry PK**, Lukina E, Ben Turkia H, Shankar SP, Baris H, Ghosn M, Mehta A, Packman S,Pastores G, Petakov M, Assouline S, Balwani M, Danda S, Hadjiev E, Ortega A, Gaemers SJM, Tayaq R, Peterschmitt, MJ. Outcomes after 18-months of Eliglustat Therapy in Treatment-Naïve Adults with Gaucher Disease Type 1: The Phase 3 ENGAGE Trial. *Amer J Hematol*, 2017; 92(11); 1170-1176. Doi 10.1002/ajh.24877 PMID 28762527
74. [Taguchi, Y.V.](https://www.scopus.com/authid/detail.uri?authorId=57192916355), [Liu, J.](https://www.scopus.com/authid/detail.uri?authorId=56097923800), [Ruan, J.](https://www.scopus.com/authid/detail.uri?authorId=7102526938), ...[Mistry, P.K.](https://www.scopus.com/authid/detail.uri?authorId=7006611107), [Chandra, S.S.](https://www.scopus.com/authid/detail.uri?authorId=55612029800) Glucosylsphingosine promotes α-synuclein pathology in mutant GBA-associated parkinson’s disease. [Journal of Neuroscience](https://www.scopus.com/sourceid/16764?origin=resultslist), 2017, 37(40), pp.9617-9631
75. McGovern MM, Dionisi-Vici C, Giugliani R, Hwu P, Lidove O, Lukacs Z, Eugen Mengel K, **Mistry PK**, Schuchman EH, Wasserstein MP. Consensus recommendation for a diagnostic guideline for acid sphingomyelinase deficiency. *Genet Med*. 2017; 19(9): 967-974. doi: 10.1038/gim.2017.7. PMID: 28406489
76. Regenbook M, Van Dussen L, Verheij J, Weinreb NJ, Santosa D, Vom Dahl S, Haussinger D, Muller MN, canbay A, Rigoldi M, Piperno A, Dinur T, Zimran A, **Mistry PK**, Salah KY, Belmatoug N, Kuter DJ, Hollak CEM. Hepatocellular Carcinoma in Gaucher Disease: An International Case Series. *J Inherit Metab Dis*.2018; doi: 10.1007/s10545-018-0142-y (Epub ahead of print)
77. Weinreb NJ, **Mistry PK**, Rosenbloom BE, Dhodapkar MV. MGUS, Lymphoplasmacytic Malignancies, and Gaucher Disease: The significance of the Clinical Association. *Blood*. 2018; 131(22): 2500-2501. PMID: 29650800
78. Nair S, Sng J, Boddupalli CS, Seckinger A, Chesi M, Fulciniti M, Zhang L, Rauniyar N, Lopez M, Neparidze N, Parker T, Munshi NC, Sexton R, Barlogie B, Orlowski R, Bergsagel L, Hose D, Flavell RA, **Mistry PK**, Meffre E, Dhodapkar MV. Antigen-Mediated Regulation in Monoclonal Gammopathies and Myeloma. *JCI Insight*. 2018; 3(8). PMID 29669929
79. **Mistry PK**, Balwani M, Baris HN, Turkia HB, Burrow TA, Charrow J, Cox GF, Dada S, Dragosky M, Drelichman G, El-Beshlawy A, Fraga C, Freisens S, Gaemers S, Hadjiev E, Kishnani PS, Lukina E, Maison-Blanche P, Martins AM, Pastores G, Petakov M, Peterschmitt MJ, Rosenbaum H, Rosenbloom B, Underhill LH, Cox TM. Safety,Efficacy, and Authorization of Eliglustat as a First-Line Therapy in Gaucher Disease Type 1. *Blood Cells Mol Dis*. 2018; 71:71-74. No abstract available. PMID:29680197
80. Hakim A, Zhang X, DeLisle A, Oral EA, Dykas D, Drzewiecki K, Assis DN, Silveira M, Batisti J, Jain D, Bale A, **Mistry PK**, Vilarinho S. [Clinical utility of genomic analysis in adults with idiopathic liver disease.](https://www.ncbi.nlm.nih.gov/pubmed/31000363) J Hepatol. 2019 Jun;70(6):1214-1221. doi: 10.1016/j.jhep.2019.01.036. Epub 2019 Apr 15. PMID: 31000363
81. [Afinogenova, Y.](https://www.scopus.com/authid/detail.uri?authorId=55270238300), [Ruan, J.](https://www.scopus.com/authid/detail.uri?authorId=7102526938), [Yang, R.](https://www.scopus.com/authid/detail.uri?authorId=18435553800), ...[Lischuk, A.](https://www.scopus.com/authid/detail.uri?authorId=54918461600), [Mistry, P.K.](https://www.scopus.com/authid/detail.uri?authorId=7006611107) Aberrant progranulin, YKL-40, cathepsin D and cathepsin S in Gaucher disease.

[Molecular Genetics and Metabolism](https://www.scopus.com/sourceid/14155?origin=resultslist), 2019, 128(1-2), pp.62-67

1. [Beshlawy, A.E.](https://www.scopus.com/authid/detail.uri?authorId=6603278914), [Murugesan, V.](https://www.scopus.com/authid/detail.uri?authorId=56530370100), [Mistry, P.K.](https://www.scopus.com/authid/detail.uri?authorId=7006611107), [Eid, K.](https://www.scopus.com/authid/detail.uri?authorId=12804271300) Reversal of life-threatening hepatopulmonary syndrome in Gaucher disease by imiglucerase enzyme replacement therapy. [Molecular Genetics and Metabolism Reports](https://www.scopus.com/sourceid/21100326555?origin=resultslist), 2019, 20, 100490
2. [Vujosevic, S.](https://www.scopus.com/authid/detail.uri?authorId=6603110578), [Medenica, S.](https://www.scopus.com/authid/detail.uri?authorId=33568078600), [Vujicic, V.](https://www.scopus.com/authid/detail.uri?authorId=57209467088), ...[Liu, J.](https://www.scopus.com/authid/detail.uri?authorId=56097923800), [Mistry, P.K.](https://www.scopus.com/authid/detail.uri?authorId=7006611107) Gaucher disease in Montenegro - genotype/phenotype correlations: Five cases report.

[World Journal of Clinical Cases](https://www.scopus.com/sourceid/21100874917?origin=resultslist), 2019, 7(12), pp.1475-1482

1. N[air, S.](https://www.scopus.com/authid/detail.uri?authorId=15842089200), [Bar, N.](https://www.scopus.com/authid/detail.uri?authorId=56966437700), [Xu, M.L.](https://www.scopus.com/authid/detail.uri?authorId=7403607301), ...[Dhodapkar, M.](https://www.scopus.com/authid/detail.uri?authorId=7003286705), [Mistry, P.K.](https://www.scopus.com/authid/detail.uri?authorId=7006611107) Glucosylsphingosine but not Saposin C, is the target antigen in Gaucher disease-associated gammopathy. [Molecular Genetics and Metabolism](https://www.scopus.com/sourceid/14155?origin=resultslist), 2020, 129(4), pp.286-291
2. [Gao, E.](https://www.scopus.com/authid/detail.uri?authorId=57216646956), [Cheema, H.](https://www.scopus.com/authid/detail.uri?authorId=16400954500), [Waheed, N.](https://www.scopus.com/authid/detail.uri?authorId=57088264100" \o "), ...[Lifton, R.P.](https://www.scopus.com/authid/detail.uri?authorId=7005891012), [Vilarinho, S.](https://www.scopus.com/authid/detail.uri?authorId=6507389489) Organic Solute Transporter Alpha Deficiency: A Disorder With Cholestasis, Liver Fibrosis, and Congenital Diarrhea. [Hepatology (Baltimore, Md.)](https://www.scopus.com/sourceid/28371?origin=resultslist), 2020, 71(5), pp.1879-1882
3. [Raskovalova, T.](https://www.scopus.com/authid/detail.uri?authorId=8963644300), [Deegan, P.B.](https://www.scopus.com/authid/detail.uri?authorId=8558838100), [Mistry, P.K.](https://www.scopus.com/authid/detail.uri?authorId=7006611107), ...[Labarère, J.](https://www.scopus.com/authid/detail.uri?authorId=7004528578" \o "), [Berger, M.G.](https://www.scopus.com/authid/detail.uri?authorId=7404267974)

[Accuracy of chitotriosidase activity and CCL18 concentration in assessing type I Gaucher disease severity. A systematic review with meta-analysis of individual participant data](https://www.scopus.com/record/display.uri?eid=2-s2.0-85083383198&origin=resultslist). [Haematologica](https://www.scopus.com/sourceid/25954?origin=resultslist), 2020, 105(5)

1. [Mistry, P.K.](https://www.scopus.com/authid/detail.uri?authorId=7006611107), [Balwani, M.](https://www.scopus.com/authid/detail.uri?authorId=22133289200), [Charrow, J.](https://www.scopus.com/authid/detail.uri?authorId=7004262624), ...[Underhill, L.H.](https://www.scopus.com/authid/detail.uri?authorId=26027306700), [McClain, M.R.](https://www.scopus.com/authid/detail.uri?authorId=57217388077) Real-world effectiveness of eliglustat in treatment-naïve and switch patients enrolled in the International Collaborative Gaucher Group Gaucher Registry.[American Journal of Hematology](https://www.scopus.com/sourceid/25424?origin=resultslist), 2020, 95(9), pp.1038-1046
2. Fierro L, Nesheiwat N, Naik H, Narayanan P, Mistry PK, Balwani M. Gaucher disease and SARS-CoV-2 infection: Experience from 181 patients in New York. Mol Genet Metab. 2021 Jan;132(1):44-48. doi: 10.1016/j.ymgme.2020.12.288. Epub 2020 Dec 15. PMID: 33353808; PMCID: PMC7834197.
3. Mistry PK, Balwani M, Charrow J, Kishnani P, Niederau C, Underhill LH, McClain MR. Real-world effectiveness of eliglustat in treatment-naïve and switch patients enrolled in the International Collaborative Gaucher Group Gaucher Registry. Am J Hematol. 2020 Sep;95(9):1038-1046. doi: 10.1002/ajh.25875. Epub 2020 Jun 24. PMID: 32438452; PMCID: PMC7497238.
4. Weinreb NJ, Camelo JS Jr, Charrow J, McClain MR, Mistry P, Belmatoug N; International Collaborative Gaucher Group (ICGG) Gaucher Registry (NCT00358943) investigators. Gaucher disease type 1 patients from the ICGG Gaucher Registry sustain initial clinical improvements during twenty years of imiglucerase treatment. Mol Genet Metab. 2021 Feb;132(2):100-111. doi: 10.1016/j.ymgme.2020.12.295. Epub 2021 Jan 8. PMID: 33485799.

**REVIEWS/EDITORIALS:**

1. Mistry P, Balwani M, Barbouth D, Burrow TA, Ginns EI, Goker-Alpan O, Grabowski GA, Kartha RV, Kishnani PS, Lau H, Lee CU, Lopez G, Maegawa G, Packman S, Prada C, Rosenbloom B, Lal TR, Schiffmann R, Weinreb N, Sidransky E. Gaucher disease and SARS-CoV-2 infection: Emerging management challenges. Mol Genet Metab. 2020 Jul;130(3):164-169. doi: 10.1016/j.ymgme.2020.05.002. Epub 2020 May 11. PMID: 32471800; PMCID: PMC7211677.
2. Jones SA, McGovern M, Lidove O, Giugliani R, Mistry PK, Dionisi-Vici C, Munoz-Rojas MV, Nalysnyk L, Schecter AD, Wasserstein M. Clinical relevance of endpoints in clinical trials for acid sphingomyelinase deficiency enzyme replacement therapy. Mol Genet Metab. 2020 Sep-Oct;131(1-2):116-123. doi: 10.1016/j.ymgme.2020.06.008. Epub 2020 Jun 24. PMID: 32616389.
3. Grabowski GA, Antommaria AHM, Kolodny EH, Mistry PK. Gaucher disease: Basic and translational science needs for more complete therapy and management. Mol Genet Metab. 2021 Feb;132(2):59-75. doi: 10.1016/j.ymgme.2020.12.291. Epub 2020 Dec 29. PMID: 33419694.
4. [Narayanan, P.](https://www.scopus.com/authid/detail.uri?authorId=57217691581), [Mistry, P.K.](https://www.scopus.com/authid/detail.uri?authorId=7006611107) Update on Alpha-1 Antitrypsin Deficiency in Liver Disease. [Clinical Liver Disease](https://www.scopus.com/sourceid/21100254589?origin=resultslist), 2020, 15(6), pp.228-235
5. [Mistry, P.](https://www.scopus.com/authid/detail.uri?authorId=7006611107), [Balwani, M.](https://www.scopus.com/authid/detail.uri?authorId=22133289200), [Barbouth, D.](https://www.scopus.com/authid/detail.uri?authorId=12809381600" \o "), ...[Weinreb, N.](https://www.scopus.com/authid/detail.uri?authorId=6701772984), [Sidransky, E.](https://www.scopus.com/authid/detail.uri?authorId=7005375809) Gaucher disease and SARS-CoV-2 infection: Emerging management challenges. [Molecular Genetics and Metabolism](https://www.scopus.com/sourceid/14155?origin=resultslist), 2020, 130(3), pp.164-169
6. [Olave, M.C.](https://www.scopus.com/authid/detail.uri?authorId=57215009194), [Gurung, A.](https://www.scopus.com/authid/detail.uri?authorId=55523417800), [Mistry, P.K.](https://www.scopus.com/authid/detail.uri?authorId=7006611107), ...[Torbenson, M.](https://www.scopus.com/authid/detail.uri?authorId=7004312220" \o "), [Jain, D.](https://www.scopus.com/authid/detail.uri?authorId=7202913084) Etiology of cirrhosis in the young. [Human Pathology](https://www.scopus.com/sourceid/14024?origin=resultslist), 2020, 96, pp.96-103
7. [Drelichman, G.](https://www.scopus.com/authid/detail.uri?authorId=7801427001), [Castañeda-Hernández, G.](https://www.scopus.com/authid/detail.uri?authorId=7004499281" \o "), [Cem Ar, M.](https://www.scopus.com/authid/detail.uri?authorId=57212507378), ...[Freisens, S.](https://www.scopus.com/authid/detail.uri?authorId=57202019666), [Mistry, P.K.](https://www.scopus.com/authid/detail.uri?authorId=7006611107) The road to biosimilars in rare diseases - ongoing lessons from Gaucher disease. [American Journal of Hematology](https://www.scopus.com/sourceid/25424?origin=resultslist), 2020, 95(3), pp.233-237
8. Jones, S.A., McGovern, M., Lidove, O., ...Schecter, A.D., Wasserstein, M.

Clinical relevance of endpoints in clinical trials for acid sphingomyelinase deficiency enzyme replacement therapy. Molecular Genetics and Metabolism, 2020

1. Vilarinho, S., Mistry, P.K. Exome Sequencing in Clinical Hepatology

Hepatology, 2019, 70(6), pp.2185-2192

1. [Hughes, D.](https://www.scopus.com/authid/detail.uri?authorId=55186237200), [Mikosch, P.](https://www.scopus.com/authid/detail.uri?authorId=55636245500), [Belmatoug, N.](https://www.scopus.com/authid/detail.uri?authorId=7003564362), ...[Weinreb, N.](https://www.scopus.com/authid/detail.uri?authorId=6701772984), [Deegan, P.](https://www.scopus.com/authid/detail.uri?authorId=8558838100) Gaucher Disease in Bone: From Pathophysiology to Practice. [Journal of Bone and Mineral Research](https://www.scopus.com/sourceid/12211?origin=resultslist), 2019, 34(6), pp.996-1013
2. [Wasserstein, M.](https://www.scopus.com/authid/detail.uri?authorId=6601974880), [Dionisi-Vici, C.](https://www.scopus.com/authid/detail.uri?authorId=7006329633), [Giugliani, R.](https://www.scopus.com/authid/detail.uri?authorId=7005600401), ...[Schuchman, E.H.](https://www.scopus.com/authid/detail.uri?authorId=7004364820), [McGovern, M.](https://www.scopus.com/authid/detail.uri?authorId=35596688500) Recommendations for clinical monitoring of patients with acid sphingomyelinase deficiency (ASMD)[Molecular Genetics and Metabolism](https://www.scopus.com/sourceid/14155?origin=resultslist), 2019, 126(2), pp.98-105
3. Puri RD, Kapoor S, Kishnani PS, Dalal A, Gupta N, Muranjan M, Phadke SR, Sachdeva A, Verma IC, **Mistry PK**; Gaucher Disease Task Force. Diagnosis and Management of Gaucher Disease in India- Consensus Guidelines of the Gaucher Disease Task Force of the Society for Indian Academy of Medical Genetics and the Indian Academy of Pediatrics. *Indian Pediatr*.2018: 55(2): 143-153. PMID 29503270
4. Mistry PK, Lopez G, Schiffmann R, Barton NW, Weinreb NJ, Sidransky E.Gaucher disease: Progress and ongoing challenges. Mol Genet Metab. 2017 Jan - Feb;120(1-2):8-21. doi: 10.1016/j.ymgme.2016.11.006. Epub 2016 Nov 17. Review. PMID: 27916601
5. Desnick RJ, Barton NW, Furbish S, Grabowski GA, Karlsson S, Kolodny EH, Medin JA, Murray GJ, Mistry PK, Patterson MC, Schiffmann R, Weinreb NJ. Roscoe Owen Brady, MD: Remembrances of co-investigators and colleagues. Mol Genet Metab. 2017 Jan - Feb;120(1-2):1-7. doi: 10.1016/j.ymgme.2016.10.010. Epub 2016 Nov 12. Review.PMID: 27866832
6. Cohen IJ, Baris H, Mistry PK, Sands MS Overcoming the Next Barriers to Successful Therapy. Pediatr Endocrinol Rev. 2016 Jun;13 Suppl 1:629. PMID: 27491209
7. **Mistry** **PK**, Belmatoug N, vom Dahl S , Guilliani R (2015) *Natural history of Gaucher disease: insights from the ICGG Registry* Amer J Hematology 90 Suppl 1:S6-S11. PMID: 26096746
8. **Mistry PK**, Taddei T, vom Dahl S, Rosenbloom BE. *Gaucher disease and malignancy: a model for cancer pathogenesis in an inborn error of metabolism*. Crit Rev Oncog. 2013. 18(3):235-46. PMID: 23510066
9. Cohen IJ, Baris H, **Mistry PK**. *Treatment for LSDs: no longer just enzyme replacement therapy for Gaucher disease. Foreword.* Pediatr Endocrinol Rev. 2013 Nov. 11 Suppl 1:58. PMID: 24380122
10. Barranger JA, Brady RO, Grabowski GA, Mankin H, **Mistry PK**, Weinreb NJ. Am J Hematol. *Position statement: National Gaucher Foundation Medical Advisory Board, January 7, 2014*. 2014 May. 89(5):457-8. PMID: 24488939
11. **Mistry** **PK** (2013) *Rare disease clinical research network's urea cycle consortium delivers a successful clinical trial to improve alternate pathway therapy*.Hepatology. 2013 Jun;57(6):2100-2
12. **Mistry** **PK**, Weinthal JA, Weinreb NJ.(2012)*Disease state awareness in Gaucher disease: a Q&A expert roundtable discussion*. Clin Adv Hematol Oncol. 2012 Jun;10(6 Suppl 8):1-16.
13. **Mistry** **PK**, Taddei T, vom Dahl S and Rosenbloom B (2012) *Malignancy in Gaucher disease: a model of increased cancer risk in an inborn error of metabolism*. *Critical Reviews in Oncogenesis* (in press)
14. **Mistry** **PK**, Weinreb NJ, Brady RO, Grabowski GA., *Gaucher disease: resetting the clinical and scientific agenda.* Am J Hematol, 2009. 84(4): p. 205-7.
15. Weinreb NJ, Andersson HC, Banikazemi M, Barranger J, Beutler E, Charrow J, Grabowski GA, Hollak CE, Kaplan P, Mankin H, **Mistry** **PK**, Rosenbloom BE, Vom Dahl S, Zimran A., *Prevalence of type 1 Gaucher disease in the United States.* Arch Intern Med, 2008. 168(3): p. 326-7; author reply 327-8.
16. Cox TM, Aerts JM, Belmatoug N, Cappellini MD, vom Dahl S, Goldblatt J, Grabowski GA, Hollak CE, Hwu P, Maas M, Martins AM, **Mistry** **PK**, Pastores GM, Tylki-Szymanska A, Yee J, Weinreb N., *Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring.* J Inherit Metab Dis, 2008. 31(3): p. 319-36.
17. Taddei T, **Mistry** **P**, Schilsky ML., *Inherited metabolic disease of the liver.* Curr Opin Gastroenterol, 2008. 24(3): p. 278-86
18. **Mistry** **P**, Germain DP., *Therapeutic objectives in Gaucher disease.* Rev Med Interne, 2007. 28 Suppl 2: p. S171-5.
19. **Mistry** **P**, Germain DP.*Therapeutic goals in Gaucher disease.* Rev Med Interne, 2006. 27 Suppl 1: p. S30-8.
20. **Mistry** **P**, Germain DP., *Phenotype variations in Gaucher disease.* Rev Med Interne, 2006. 27 Suppl 1: p. S3-10.
21. Andersson HC, Charrow J, Kaplan P, **Mistry** **P**, Pastores GM, Prakesh-Cheng A, Rosenbloom BE, Scott CR, Wappner RS, Weinreb NJ; *International Collaborative Gaucher Group U.S. Regional Coordinators.Individualization of long-term enzyme replacement therapy for Gaucher disease.*
Genet Med. 2005 Feb;7(2):105-10.
22. Weinreb NJ, Barranger JA, Charrow J, Grabowski GA, Mankin HJ, **Mistry** **P**., *Guidance on the use of miglustat for treating patients with type 1 Gaucher disease.* Am J Hematol, 2005. 80(3): p. 223-9.
23. Charrow J, Andersson HC, Kaplan P, Kolodny EH, **Mistry** **P**, Pastores G, Prakash-Cheng A, Rosenbloom BE, Scott CR, Wappner RS, Weinreb NJ., *Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease: consensus recommendations.* J Pediatr, 2004. 144(1): p. 112-20.
24. Pastores GM, Weinreb NJ, Aerts H, Andria G, Cox TM, Giralt M, Grabowski GA, **Mistry** **PK**, Tylki-Szymańska A., *Therapeutic goals in the treatment of Gaucher disease.* Semin Hematol, 2004. 41(4 Suppl 5): p. 4-14.
25. Weinreb NJ, Aggio MC, Andersson HC, Andria G, Charrow J, Clarke JT, Erikson A, Giraldo P, Goldblatt J, Hollak C, Ida H, Kaplan P, Kolodny EH, **Mistry** **P**, Pastores GM, Pires R, Prakash-Cheng A, Rosenbloom BE, Scott CR, Sobreira E, Tylki-Szymańska A, Vellodi A, vom Dahl S, Wappner RS, Zimran A; International Collaborative Gaucher Group (ICGG)., *Gaucher disease type 1: revised recommendations on evaluations and monitoring for adult patients.* Semin Hematol, 2004. 41(4 Suppl 5): p. 15-22.
26. **Mistry** **PK**., *Treatment of Gaucher's disease with OGT 918.* Lancet, 2000. 356(9230): p. 676-7.
27. Schilsky, ML, **Mistry** **PK**.,*Inherited metabolic disease.* Curr Opin Gastroenterol, 2000. 16(3): p. 219-30.
28. **Mistry** **PK**., *Gaucher's disease: a model for modern management of a genetic disease*. J Hepatol, 1999. 30 Suppl 1: p. 1-5.
29. **Mistry** **PK**, Abrahamov A., *A practical approach to diagnosis and management of Gaucher's disease.* Baillieres Clin Haematol, 1997. 10(4): p. 817-38.
30. **Mistry** **PK**., *Genotype/phenotype correlations in Gaucher's disease*. Lancet, 1995. 346(8981): p. 982-3.
31. **Mistry** **PK**, Cox TM., *The glucocerebrosidase locus in Gaucher's disease: molecular analysis of a lysosomal enzyme*. J Med Genet, 1993. 30(11): p. 889-94

**BOOK CHAPTERS, ETC:**

1. Mistry PK, Thurberg B and Grabowski GA. Lysosomal Storage Disorders in Children, Chapter 32 in Liver Disease in Children: 5th edition Edited by Frederick J. Suchy, University of Colorado, Children’s Hospital Colorado, Aurora, Ronald J. Sokol, University of Colorado, Children’s Hospital Colorado, Aurora, William F. Balistreri, Cincinnati Children’s Hospital Medical Center, Cincinnati. Edited in association with Jorge A. Bezerra, Cincinnati Children’s Hospital Medical Center, Cincinnati, Cara L. Mack, University of Colorado, Children’s Hospital Colorado, Aurora, Benjamin L. Shneider, Texas Children’s Hospital, Houston
2. [Goobie, G.C.](https://www.scopus.com/authid/detail.uri?authorId=57208532821), [Sirrs, S.M.](https://www.scopus.com/authid/detail.uri?authorId=6602739880), [Yee, J.](https://www.scopus.com/authid/detail.uri?authorId=7203044535), ...[Paquin, W.](https://www.scopus.com/authid/detail.uri?authorId=55514129300), [Levy, R.D.](https://www.scopus.com/authid/detail.uri?authorId=56346702100) Lessons from lung transplantation: Cause for redefining the pathophysiology of pulmonary hypertension in gaucher disease. [Respiratory Medicine Case Reports](https://www.scopus.com/sourceid/21100203501?origin=resultslist), 2019, 28, 100893
3. **Mistry** **PK** and Jain D (2011) *'Hematology of liver disease'* in Sherlock's Disease of the Liver and Biliary System. Eds JS Dooley, ASF Lok, AK Burroughs, EJ Heathcote. Wiley-Blakwell.
4. Schilsky M and **Mistry** **PK** (2010) *'Wilson disease and Menke Disease in Oxford Textbook of Medicine*. Eds DA Warrell. TM Cox, JD Firth. Oxford University Press.
5. Schilsky M and **Mistry PK**. (2008)*Wilson disease for Genetic Diseases of the Kidney*, Eds RP Lifton, S Somlo, G Giebisch and D Seldin . Elsevier Inc
6. **Mistry** **PK** and Zimran A: *Clinical features and natural history of Gaucher disease in ‘Gaucher disease’* Eds Futerman and Zimran A, CRC Press (2005).
7. Grabowski GA, **Mistry** **P.K**. and ICGG investigators. *Phenotypic spectrum of Gaucher disease*. Chapter 146.1, Metabolic and Molecular Bases of Inherited disease, Eds Scriver CM, Beudet AL, Sly WS and Valle D, McGraw Hill; http://www.ommbid.com (2005)
8. McGovern MM and **Mistry** **PK** (2001*) Lysosomal storage diseases* in *Liver Disease in Children 2nd* Edition Eds FJ Suchy, RJ Sokol, WF Balistreri. Lippincott Williams & Wilkins.
9. **Mistry** **PK** and Hoffbrand AVH. *The liver in intracellular and extracelluar lipidosis*. Chapter 19.7 in *Oxford Textbook of Clinical Hepatology Second Edition 1999* Eds Bircher J, Benhamou J-P, McIntyre N, Rizzetto M and Rodes J.
10. **Mistry** **PK** and Abrahamov. *A practical approach to diagnosis and management of Gaucher disease*. In *Gaucher’s Disease Ed A Zimran : Bailliere’s Clinical Hematology* 1997.
11. Schilsky M and **Mistry** **P** *Inherited metabolic liver diseases* in *Curr Opinion Gastro: Liver Diseases*, Ed: Moseley, R.H., Lippincott, Williams & Wilkins, 2001: 221-231.
12. Schilsky M and Mistry PK. Wilson disease in Oxford Textbook of Medicine. 6th Edition, 2019 Eds D. A. Warrell; T. M. Cox; J. D. Firth

Updated: 05.29.2021